There is a lot of innovation in the US healthcare industry concerning ways to manage the care for specialty populations, but there still needs to be a way to regulate these innovative models. Matt Salo pointed out that for so long the financial incentives have not been there to get people healthy and keep them there, and meanwhile only a small part of the population accounts for half of the total costs.
“That’s the Holy Grail,” Salo said. “If we can figure out how to improve the care and bring the cost down for that group, then we’ll have figured all this out.”
Unfortunately, with all the emerging models out there, data is not being shared across boundaries and entities are caring for part of a person instead of the whole person, said Margaret E. O’Kane.
“I think the challenge is catching up with [current innovation], assessing it in a hard-nosed way, and really being able to make comparisons,” O’Kane said. “Part of the problem with a proliferation of innovation is that everybody’s doing something different and they’re all measuring it in a different way.”
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More